Zenith Drugs Limited was originally incorporated on November 15, 2000 as a Private Limited Company as "Zenith Drugs Private Limited" issued by the Registrar of Companies, in the State of Madhya Pradesh, Gwalior. Subsequently, Company was converted into Public Limited and consequently, the name of the Company was changed to `Zenith Drugs Limited` pursuance to issuance of a Fresh Certificate of Incorporation on September 13, 2023 by the Registrar of Companies, Gwalior.
Zenith are a reputable pharmaceutical manufacturing and trading unit based out from Indore. Zenith`s core business centers on production
of high-quality, cost-effective pharmaceutical formulations such as: ORS Powder; Liquid Orals; Oinments; Liquid Externals and Capsules. With a diverse portfolio of formulations, the Company is specialized in manufacturing affordable and high quality medicines to meet the needs of patients.
The Company was established in 2000 by the founders, Late Shri Ramniklal Soni, and Mr. Mukesh Jain. Initially in 2001, Company started as a modest manufacturing house for oral and external formulations. However, recognizing the importance of quality and compliance, the Company swiftly shifted to a Schedule M GMP compliant unit in 2004 where it started the production of two lines which are liquid orals and ointments. In 2007, it expanded the product line by incorporating ORS Powder manufacturing into their operations. In 2016, the Company established present manufacturing facility, which holds WHO GMP certification. In 2019, it expanded the product line by introducing liquid externals and capsules.
The Company raised money from public by issuing 51,48,800 Equity Shares amounting to Rs 40.68 Cr. through fresh issue on February 22, 2024.
In FY 2024-25, Company diversified its product portfolio by entering the tablet manufacturing segment and investing in new infrastructure to support this growth.
Also, Company is in the process of establishing direct export distribution in Liberia for the product BVM`s Oral Rehydration Salts B.P. 27.9g. This strategic initiative allows them to have more control over the export process and establish a direct presence in the Liberian market, ensuring seamless delivery of their products.
Zenith Drugs share price as on 02 Mar 2026 is Rs. 49. Over the past 6 months, the Zenith Drugs share price has decreased by 28.93% and in the last one year, it has decreased by 27.19%. The 52-week low for Zenith Drugs share price was Rs. 44.5 and 52-week high was Rs. 107.
Zenith Drugs Limited was originally incorporated on November 15, 2000 as a Private Limited Company as "Zenith Drugs Private Limited" issued by the Registrar of Companies, in the State of Madhya Pradesh, Gwalior. Subsequently, Company was converted into Public Limited and consequently, the name of the Company was changed to `Zenith Drugs Limited` pursuance to issuance of a Fresh Certificate of Incorporation on September 13, 2023 by the Registrar of Companies, Gwalior.
Zenith are a reputable pharmaceutical manufacturing and trading unit based out from Indore. Zenith`s core business centers on production
of high-quality, cost-effective pharmaceutical formulations such as: ORS Powder; Liquid Orals; Oinments; Liquid Externals and Capsules. With a diverse portfolio of formulations, the Company is specialized in manufacturing affordable and high quality medicines to meet the needs of patients.
The Company was established in 2000 by the founders, Late Shri Ramniklal Soni, and Mr. Mukesh Jain. Initially in 2001, Company started as a modest manufacturing house for oral and external formulations. However, recognizing the importance of quality and compliance, the Company swiftly shifted to a Schedule M GMP compliant unit in 2004 where it started the production of two lines which are liquid orals and ointments. In 2007, it expanded the product line by incorporating ORS Powder manufacturing into their operations. In 2016, the Company established present manufacturing facility, which holds WHO GMP certification. In 2019, it expanded the product line by introducing liquid externals and capsules.
The Company raised money from public by issuing 51,48,800 Equity Shares amounting to Rs 40.68 Cr. through fresh issue on February 22, 2024.
In FY 2024-25, Company diversified its product portfolio by entering the tablet manufacturing segment and investing in new infrastructure to support this growth.
Also, Company is in the process of establishing direct export distribution in Liberia for the product BVM`s Oral Rehydration Salts B.P. 27.9g. This strategic initiative allows them to have more control over the export process and establish a direct presence in the Liberian market, ensuring seamless delivery of their products.
Zenith Drugs share price as on 02 Mar 2026 is Rs. 49. Over the past 6 months, the Zenith Drugs share price has decreased by 28.93% and in the last one year, it has decreased by 27.19%. The 52-week low for Zenith Drugs share price was Rs. 44.5 and 52-week high was Rs. 107.
